News | Heart Valve Technology | October 04, 2019

Study Finds Sustained Benefit for TAVR vs. SAVR at One Year

Results from the PARTNER 3 Quality of Life Sub-study presented at TCT 2019

A Sapien 3 TAVR valve in position as seen under GE Assist guidance on angiography. Study Finds Sustained Benefit for TAVR vs. SAVR at One Year. #TCT2019 #TCT19

A Sapien 3 TAVR valve in position as seen under GE Assist guidance on angiography.


October 4, 2019 – A new analysis of the PARTNER 3 Trial data found a modest, but significant, improvement in one-year disease-specific quality of life after transcatheter aortic valve replacement (TAVR) compared with surgical aortic valve replacement (SAVR) in low-risk patients with severe aortic stenosis (AS). Findings were reported at the 2019 Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. The results were also published simultaneously in the Journal of the American College of Cardiology.[1]

The randomized PARTNER 3 trial demonstrated that TAVR with the Sapien 3 valve resulted in lower rates of death, and re-hospitalization at one year compared with SAVR in patients with severe AS at low surgical risk. However, the effect of treatment strategy on early and late health-related quality of life in this population is unknown.

“This is the first randomized trial to demonstrate a persistent, albeit modest, disease-specific health status advantage with TAVR at six and 12 months – time points at which patients are assumed to have recovered fully from surgery,” said Suzanne J. Baron, M.D., MSc, director of interventional cardiology research at Lahey Hospital and Medical Center in Burlington, Mass. “Further studies are needed to evaluate the durability of health status benefits with TAVR compared with SAVR beyond one year in this low-risk population.”

The researchers compared health status at one, six and 12 months in low risk patients with severe AS treated with either TAVR or SAVR in the PARTNER 3 trial. The analysis found that over the one-year follow-up period, treatment with either TAVR or SAVR resulted in substantial improvements in both disease-specific and generic health status compared with baseline, despite most patients having only NYHA Class I or II symptoms at baseline. Consistent with previous studies of transfemoral TAVR, TAVR was associated with significantly better health status than SAVR at one month on all scales (mean difference in KCCQ-OS 16.0 points; p<0.001). However, in contrast to prior studies, the researchers observed a persistent, although attenuated, benefit of TAVR over SAVR in disease-specific health status at six and 12 months (mean difference in KCCQ-OS 2.6 and 1.8 points respectively; p<0.04 for both).

In analyses that incorporated both survival and change in health status together, TAVR also demonstrated a significant health status benefit compared with SAVR at all time points (p<0.05). 

Exploratory analyses demonstrated that the late health status benefits seen with TAVR were driven by a difference in the proportion of patients who experienced a large (i.e., ≥20 point) improvement in the KCCQ score. These benefits may be explained, in part, by differential rates of post-procedural complications between TAVR and SAVR.

The PARTNER 3 Quality of Life Substudy was funded by Edwards Lifesciences. Baron disclosed research funding and advisory board compensation from Boston Scientific Corp and consulting fees from Edwards Lifesciences. 

Find information on other late-breaking TCT trials

Reference:

1. Suzanne J. Baron, Elizabeth A. Magnuson, Michael Lu, et al. Health Status after Transcatheter vs. Surgical Aortic Valve Replacement in Low-Risk Patients with Aortic Stenosis. Journal of the American College of Cardiology. September 2019. DOI: 10.1016/j.jacc.2019.09.007

 


Related Content

News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — A programing algorithm, being tested by HonorHealth Research Institute for those patients with new or ...

Home June 20, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home June 12, 2024
Home
News | Cardiovascular Clinical Studies

June 6, 2024 —Cleveland Clinic researchers found higher amounts of the sugar alcohol xylitol are associated with ...

Home June 06, 2024
Home
News | Cardiovascular Clinical Studies

May 31, 2024 — CareDx, a leading precision medicine company focused on the discovery, development, and commercialization ...

Home May 31, 2024
Home
News | Cardiovascular Clinical Studies

May 29, 2024 — Data was presented by AstraZeneca on AZD0780, an oral PCSK9 inhibitor which demonstrated significant LDL ...

Home May 29, 2024
Home
News | Cardiovascular Clinical Studies

May 23, 2024 — A newly-published peer-reviewed study in the Journal of the American Heart Association, JAHA, found that ...

Home May 23, 2024
Home
News | Cardiovascular Clinical Studies

May 23, 2024 — Global Heart Hub, the international alliance of heart patient organizations, announced the first findings ...

Home May 23, 2024
Home
Subscribe Now